Oral Glutamatergic Augmentation for Trauma-Related Disorders with Fluoxetine- / Bupropion-Potentiated Dextromethorphan ± Piracetam: A Four-Patient Case Series - Takeaways - MDSpire

Oral Glutamatergic Augmentation for Trauma-Related Disorders with Fluoxetine- / Bupropion-Potentiated Dextromethorphan ± Piracetam: A Four-Patient Case Series

  • By

  • Cheung, Ngo

  • April 27, 2026

  • 0 min

Share

  • 1

    Traditional monoaminergic medications often provide limited relief for PTSD and complex PTSD symptoms.

  • 2

    Glutamate-based treatments can enhance synaptic plasticity and disrupt fear-conditioned neural circuits.

  • 3

    Four patients with hard-to-treat trauma-related disorders showed symptom improvement using dextromethorphan with fluoxetine.

  • 4

    Patients experienced reductions in intrusive memories, rumination, somatic pain, and functional disability without severe side effects.

  • 5

    The findings suggest the need for further controlled studies on oral NMDA–AMPA modulators for trauma-related conditions.

Original Source(s)

Oral Glutamatergic Augmentation for Trauma-Related Disorders with Fluoxetine- / Bupropion-Potentiated Dextromethorphan ± Piracetam: A Four-Patient Case Series

  • by Cheung, Ngo

  • April 27, 2026

Related Content

Baseline working memory was associated with improvement in psychological quality of life in patients with persistent depressive symptoms: a prospective observational study

Association between neurodegenerative plasma biomarkers and geriatric depression in older adults with and without clinical dementia in Kinshasa, Democratic Republic of the Congo

The effect of acceptance and commitment therapy on negative emotions and quality of life in stroke patients: a systematic review and meta-analysis